To View and Download the Conference Guide
Total Page:16
File Type:pdf, Size:1020Kb
WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES 11th Annual BIOTECH IN EUROPE INVESTOR FORUM 13th-14th September 2011 Hilton Zurich Airport Hotel, Switzerland PARTNERING ORGANISATIONS PARTNERING Conference Guide REGIONAL PARTNERS ORGANISERS www.sachsforum.com BIOTECH IN EUROPE INVESTOR FORUM WELCOME next u Welcome SPONSORS Sachs Associates are delighted to welcome you to the: VC PARTNER 11th Annual Biotech in Europe Investor Forum SPEAKERS PRESENTING COMPANIES 13th-14th September 2011 Hilton Zurich Airport Hotel, Switzerland Sachs Associates are delighted to welcome you to the 11th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry. The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 70 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners. PARTNERING ORGANISATIONS PARTNERING General Information The registration desk will be open from 8am on September 13th and from 8.15am on September 14th although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. A Networking Lunch will be set up in the Zurich A & B rooms. Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the event. REGIONAL PARTNERS ORGANISERS Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference. t WELCOME back Events Diary SPONSORS For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Zoe Harris on [email protected] VC PARTNER 5th Annual European Life Science CEO Forum For Partnering & Investing SPEAKERS PRESENTING COMPANIES 28 – 29 February 2012 • Zurich • Switzerland Back for its fifth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships. Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. The conference will feature up to 8 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives! PARTNERING ORGANISATIONS PARTNERING REGIONAL PARTNERS ORGANISERS WELCOME t SPONSORS Sponsors back :: next Global Life Science Ventures www.glsv-vc.com u VC PARTNER Investing in the life sciences Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one SPEAKERS PRESENTING COMPANIES team with a global perspective. For more information, please see our website: www.glsv-vc.com Global Life Science Ventures GmbH Von-der-Tann-Str. 3 D - 80539 München Germany Phone +49 (0)89 - 288 151-0 Fax +49 (0)89 - 288 151-30 PARTNERING ORGANISATIONS PARTNERING REGIONAL PARTNERS ORGANISERS WELCOME t SPONSORS Sponsors back :: next NYSE Euronext www.nyx.com u VC PARTNER NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company’s exchanges in Europe and the United States trade equities, futures, options, fixed- income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext’s equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – SPEAKERS PRESENTING COMPANIES represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world’s second- largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: www.nyx.com PARTNERING ORGANISATIONS PARTNERING REGIONAL PARTNERS ORGANISERS WELCOME t SPONSORS Sponsors back :: next :: Ricerca Biosciences www.ricerca.com u VC PARTNER Founded in 1986, Ricerca Biosciences offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from lead identification through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, as well as medicinal chemistry, radiochemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. Our experienced scientists deliver world-class expertise and services to help you shorten time to IND and bring molecules to the clinic faster. SPEAKERS PRESENTING COMPANIES In addition to U.S.-based facilities in Concord, Ohio, and Bothell, Washington, Ricerca also has ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon facility also holds certification from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Discovery Pharmacology Molecular profiling & screening Functional pharmacology Early cellular toxicology Cellular oncology and immune systems In vivo safety and disease models Discovery DMPK Chemical Development Medicinal chemistry Analytical chemistry Process chemistry Engineering and scale-up PARTNERING ORGANISATIONS PARTNERING Radiosynthesis API production with cGMP controls Drug Safety and Metabolism General toxicology Safety pharmacology Continuous infusion Juvenile toxicology DART Bioanalytical services Ricerca Biosciences 7528 Auburn Road Concord, OH 44077 REGIONAL PARTNERS ORGANISERS USA Tel: +1 888 RICERCA (742 3722) Fax: 440 354 6276 WELCOME SPONSORS VC Partner Merck Serono International SA www.serono.com VC PARTNER Our active ingredient is Innovation At Merck Serono, we are actively committed to bringing therapeutic innovations to patients. We specialize in the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases and other conditions with unmet medical needs. Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize SPEAKERS PRESENTING COMPANIES Merck Serono’s prescription therapies, available in over 150 countries. We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline. Specialized know-how in research and production means that we are able to ensure absolutely high-quality manufacturing, a key success factor especially in the biopharmaceutical industry. In 2007, sales of Merck Serono products generated total revenues of €4.5 billion. We devote 20% of these earnings to the pursuit of innovative new therapies through our own research and development, strategic alliances and agreement. Merck Serono S.A. 9, chemin des Mines Case postale 54 CH-1211 Geneva 20 Switzerland Tel.: +41-22-414 3000 Fax: +41-22-414 2179 PARTNERING ORGANISATIONS PARTNERING REGIONAL PARTNERS ORGANISERS WELCOME SPONSORS Speakers Tim Haines, Partner, Abingworth LLP Tim has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth VC PARTNER in September 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe. Current and past board positions include Astex Therapeutics, Fovea, IMI, KSpine, PowderMed, Stanmore